210 related articles for article (PubMed ID: 28064163)
1. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
[TBL] [Abstract][Full Text] [Related]
2. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
3. Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.
Mulder S; Perco P; Oxlund C; Mehdi UF; Hankemeier T; Jacobsen IA; Toto R; Heerspink HJL; Pena MJ
Transl Res; 2020 Aug; 222():17-27. PubMed ID: 32438071
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.
Tofte N; Lindhardt M; Adamova K; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Kooy A; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Ruggenenti PL; Rutters F; Rychlík I; Spasovski G; Speeckaert M; Trillini M; von der Leyen H; Rossing P
Diabet Med; 2018 Oct; 35(10):1375-1382. PubMed ID: 29781558
[TBL] [Abstract][Full Text] [Related]
5. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
6. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; O'Meara E; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Fang JC; Pfeffer MA; Solomon SD
Circ Heart Fail; 2018 Nov; 11(11):e005288. PubMed ID: 30571191
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial.
Curovic VR; Eickhoff MK; Rönkkö T; Frimodt-Møller M; Hansen TW; Mischak H; Rossing P; Ahluwalia TS; Persson F
Diabetes Care; 2022 Nov; 45(11):2662-2668. PubMed ID: 35998283
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes.
Oiwa A; Hiwatashi D; Takeda T; Miyamoto T; Kawata I; Koinuma M; Yamazaki M; Komatsu M
J Clin Endocrinol Metab; 2023 Aug; 108(9):2203-2210. PubMed ID: 36916985
[TBL] [Abstract][Full Text] [Related]
10. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
11. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.
Currie GE; von Scholten BJ; Mary S; Flores Guerrero JL; Lindhardt M; Reinhard H; Jacobsen PK; Mullen W; Parving HH; Mischak H; Rossing P; Delles C
Cardiovasc Diabetol; 2018 Apr; 17(1):50. PubMed ID: 29625564
[TBL] [Abstract][Full Text] [Related]
12. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
[TBL] [Abstract][Full Text] [Related]
13. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
14. [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Derer W; Dechend R; Müller DN
MMW Fortschr Med; 2010 Feb; 152(6):48-9. PubMed ID: 20302183
[No Abstract] [Full Text] [Related]
15. A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension.
Lin L; Wang C; Ren J; Mei M; Zheng L; Yang J
J Hypertens; 2023 Aug; 41(8):1306-1312. PubMed ID: 37199562
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
Nishimoto M; Ohtsu H; Marumo T; Kawarazaki W; Ayuzawa N; Ueda K; Hirohama D; Kawakami-Mori F; Shibata S; Nagase M; Isshiki M; Oba S; Shimosawa T; Fujita T
Hypertens Res; 2019 Apr; 42(4):514-521. PubMed ID: 30631161
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
18. Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.
Apperloo EM; Pena MJ; de Zeeuw D; Denig P; Heerspink HJL
Diabetes Obes Metab; 2018 Jun; 20(6):1377-1383. PubMed ID: 29345404
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
Bakris G; Yang YF; Pitt B
Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
[TBL] [Abstract][Full Text] [Related]
20. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D;
J Am Soc Nephrol; 2021 Nov; 32(11):2900-2911. PubMed ID: 34551995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]